An observational study in Cardiac Arrest (CA), Hypoxic-Ischemic Brain Injury and Post-Resuscitation Syndrome, sponsored by Chungnam National University Hospital. Active, not recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Chungnam National University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Heart Arrest with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Heart Arrest · Korea, Republic of.
Among the 44 studies in Heart Arrest with a site in Korea, Republic of, this one is the 22nd largest by enrollment of the 22 observational ones that give a count, is one of 3 that started in 2025, is one of 22 observational ones, and was the 41st registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →8 of the 44 studies in Heart Arrest with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages 18–50 · Healthy volunteers
Chungnam National University Hospital · Sites in Korea, Republic of
Ages 18+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 18+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 20–80
Korea University Ansan Hospital · Sites in Korea, Republic of
Ages 19–80 · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 200 across 376 observational studies indexed under Heart Arrest.
Median enrollment 63 across the 22 interventional studies, 195 across the 22 observational. Of the 23 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 44 have an industry lead sponsor. The 10 most frequent:
Chungnam National University Hospital is the lead sponsor of 22 studies on the registry; 13 are open to participants now.
Chungnam National University Hospital has 3 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Arrest with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07090577Chungnam National University HospitalMultiomics Profiling of CSF in Cardiac Arrest Survivors | 2026-12-31 |
| NCT07363772Seoul National University HospitalEvaluation of Mixed Reality Cardiopulmonary Resuscitation Training | 2026-12-31 |
| NCT05830422Chungnam National University HospitalPrediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological Outcomes | 2027-03-31 |
| NCT07481396Chungnam National University HospitalMolecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies in Heart Arrest with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to identify further pathophysiologic mechanism of secondary brain injury following cardiac arrest by using serial multiomics profiling of serum and cerebrospinal fluid (CSF) samples. The main question it aims to answer is:
A. The main question it aims to answer is: What are the dynamic molecular changes in serum and CSF that reflect the pathophysiological mechanisms of secondary brain injury after cardiac arrest? B. What are the differences in serum and CSF multiomic signatures between varying severities of cardiac arrest, and how are these differences associated with the underlying pathophysiological mechanisms of secondary brain injury?
Serum and CSF samples that have already been prospectively collected from participants and stored in the BioBank will be used for this analysis.
Adult patients with an out-of-hospital cardiac arrest who underwent post-resuscitation care
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cerebral Performance Category (CPC) : 1 or 2
Cerebral Performance Category (CPC) : 3 to 5
Neurological outcome
Neurological outcome is evaluated using the Cerebral Performance Category (CPC) scale. The CPC score ranges from 1 to 5, where 1 indicates good cerebral performance (normal/mild disability), 2 indicates moderate cerebral disability, 3 indicates severe cerebral disability, 4 indicates coma or vegetative state, and 5 indicates brain death. Higher scores represent a worse neurological outcome.
Time frame: after 6 months from return of spontaneous circulation
Illness severity score of cardiac arrest (rCAST)
llness severity is assessed using the revised Post-Cardiac Arrest Syndrome for Therapeutic hypothermia (rCAST) score, which incorporates initial rhythm, blood pH, lactate levels, motor response, and arrest duration. The total score ranges from 0 to 15, with higher scores indicating greater illness severity and worse prognosis. Based on the total score, patients are categorized into three severity risk groups: low severity (0-5 points), moderate severity (6-8 points), and high severity (9-15 points), where the high-severity group reflects the worst clinical prognosis and highest risk of poor outcome.
Time frame: immediately after return of spontaneous circulation
Plan to share: No — Individual participant data (IPD) will not be shared publicly due to ethical and privacy concerns. However, data sharing may be possible upon reasonable request with prior approval from the ethics committee and the principal investigator
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chungnam National University Hospital